Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Candidate symbols : Pfe save search
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Published: 2023-07-19 (Crawled : 22:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.28%
H: 0.99%
C: 0.28%
candidate vaccine publication group
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
fda candidate vaccine rsv approval potential positive
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Published: 2023-02-17 (Crawled : 08:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.14%
H: 1.12%
C: 0.75%
vla15 valneva candidate disease vaccine trial update
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
Published: 2022-12-19 (Crawled : 12:20) - globenewswire.com
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 1.48%
H: 34.31%
C: 21.9%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.23%
H: 0.56%
C: -0.31%
candidate respiratory virus
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Published: 2022-12-09 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
covid-19 fda designation candidate vaccine influenza fast track designation
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Published: 2022-12-07 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.08%
H: 2.81%
C: 0.98%
fda candidate disease vaccine application respiratory license virus review
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
ROIV | $10.6 1.34% 1.41% 4.6M
|
Manufacturing
|
| O: 7.28%
H: 2.96%
C: 0.87%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.36%
H: 1.68%
C: 1.53%
drug candidate
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
Published: 2022-12-01 (Crawled : 07:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.36%
H: 1.68%
C: 1.53%
valneva candidate disease report antibody children vaccine
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 3.11%
H: 0.88%
C: 0.02%
candidate global vaccine respiratory virus trial positive
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
Published: 2022-09-15 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.09%
H: 0.39%
C: -0.37%
candidate vaccine trial positive results
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
Published: 2022-09-07 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.13%
H: 1.12%
C: 0.94%
fda designation candidate women vaccine grants therapy infection group
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-08-25 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: 0.8%
candidate vaccine respiratory virus trial positive
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Published: 2022-08-08 (Crawled : 21:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.06%
vla15 valneva candidate disease vaccine study
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.69%
H: 0.61%
C: 0.02%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.28%
covid-19 candidate vaccine study
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.